During the past decade, St. Joseph Mercy Hospital- Inpatient Pharmacy conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "St. Joseph Mercy Hospital- Inpatient Pharmacy" are "Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive" (1 trials) and "Relapsed/Refractory Follicular Lymphoma" (1 trials). Many other conditions were trialed in "St. Joseph Mercy Hospital- Inpatient Pharmacy" in a lesser frequency.

Most popular intervention types in "St. Joseph Mercy Hospital- Inpatient Pharmacy" are "Drug" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bosutinib" (1 trials), "Imatinib" (1 trials), "Lenalidomide" (1 trials), "Placebo oral tablet" (1 trials) and "Rituximab" (1 trials). Other intervention names were less common.

The vast majority of trials in "St. Joseph Mercy Hospital- Inpatient Pharmacy" are 2 trials for "All" genders.

Currently, there are NaN active trials in "St. Joseph Mercy Hospital- Inpatient Pharmacy". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in St. Joseph Mercy Hospital- Inpatient Pharmacy, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in St. Joseph Mercy Hospital- Inpatient Pharmacy, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".